MS Look-Alikes: Which Treatments May Help Prevent Attacks

Credibility

Interest

Share:2 min read

Key Takeaway

In a large Italian study of two conditions that can look like MS, certain treatments were linked to a longer time without attacks for people with AQP4-positive NMOSD, but not for those with MOGAD.

What They Found

Researchers studied 664 people at 97 Italian centers: 406 had AQP4-positive NMOSD and 258 had MOGAD. These are rare conditions that can resemble MS but are separate diseases. People with AQP4-positive NMOSD had more difficulty with daily abilities when diagnosed, while MOGAD was more likely to begin in childhood. Rituximab was the most commonly prescribed treatment, and people with AQP4-positive NMOSD who received a type of treatment called monoclonal antibodies went longer before another attack than those receiving other treatments; this difference was not found in MOGAD. Among people taking rituximab, certain symptoms at the first attack were linked to a greater chance of another attack: spinal cord inflammation in AQP4-positive NMOSD and eye-nerve inflammation in MOGAD.

Who Should Care and Why

People told they may have MS, and their caregivers, should know that these look-alike conditions need the right diagnosis to guide care. If you have AQP4-positive NMOSD, ask your specialist how your treatment aims to prevent attacks, which are periods when symptoms suddenly appear or worsen. If you have MOGAD, do not assume a treatment finding for AQP4-positive NMOSD applies to you; the study found different results for the two groups. Tell your care team what happened during your first attack, including any vision or spinal cord problems, because that history may help them judge your risk while taking rituximab. For caregivers, keeping a simple record of new symptoms and attacks can make these conversations easier.

Important Considerations

This study looked at records of treatments people received, so it cannot prove that a treatment caused the longer time between attacks. The treatment comparison covered groups of drugs rather than showing that every drug in a group works equally well. These findings are about AQP4-positive NMOSD and MOGAD, not MS, so do not change treatment without speaking with your specialist.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Clinical Trials Caregivers

Article Topics:

MOGADMonoclonal antibodiesNMOSDRegistryRituximab

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News